Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
83.49
-0.03 (-0.04%)
Mar 6, 2026, 4:00 PM EST - Market closed
Kymera Therapeutics Stock Forecast
Stock Price Forecast
The 25 analysts with 12-month price forecasts for Kymera Therapeutics stock have an average target of 108.04, with a low estimate of 52 and a high estimate of 140. The average target predicts an increase of 29.40% from the current stock price of 83.49.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Kymera Therapeutics stock from 26 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 10 | 12 | 12 | 12 | 13 |
| Buy | 9 | 9 | 11 | 11 | 12 | 12 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 19 | 23 | 24 | 25 | 26 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $90 → $128 | Strong Buy | Maintains | $90 → $128 | +53.31% | Mar 3, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $110 → $120 | Strong Buy | Maintains | $110 → $120 | +43.73% | Mar 2, 2026 |
| Stephens & Co. | Stephens & Co. | Buy Maintains $95 → $100 | Buy | Maintains | $95 → $100 | +19.77% | Mar 2, 2026 |
| BTIG | BTIG | Strong Buy Maintains $138 → $134 | Strong Buy | Maintains | $138 → $134 | +60.50% | Feb 26, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $125 → $140 | Buy | Maintains | $125 → $140 | +67.68% | Feb 26, 2026 |
Financial Forecast
Revenue This Year
45.50M
from 39.21M
Increased by 16.05%
Revenue Next Year
47.69M
from 45.50M
Increased by 4.79%
EPS This Year
-3.78
from -3.69
EPS Next Year
-4.25
from -3.78
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 102.9M | 102.9M | |||
| Avg | 45.5M | 47.7M | |||
| Low | 9.8M | -12.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 162.5% | 126.2% | |||
| Avg | 16.0% | 4.8% | |||
| Low | -75.0% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -3.20 | -3.08 | |||
| Avg | -3.78 | -4.25 | |||
| Low | -4.13 | -6.03 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.